Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBITDA (2016 - 2026)

Sunshine Biopharma filings provide 13 years of EBITDA readings, the most recent being -$1.9 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 40.27% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.2 million, a 21.76% increase, with the full-year FY2025 number at -$5.2 million, up 21.76% from a year prior.
  • EBITDA hit -$1.9 million in Q4 2025 for Sunshine Biopharma, down from -$1.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $661452.0 in Q4 2021 to a low of -$23.3 million in Q4 2022.
  • Median EBITDA over the past 5 years was -$1.4 million (2024), compared with a mean of -$2.7 million.
  • The widest YoY moves for EBITDA: up 161.11% in 2021, down 6371.96% in 2021.
  • Sunshine Biopharma's EBITDA stood at $661452.0 in 2021, then crashed by 3618.1% to -$23.3 million in 2022, then skyrocketed by 96.74% to -$758468.0 in 2023, then tumbled by 316.2% to -$3.2 million in 2024, then surged by 40.27% to -$1.9 million in 2025.
  • The last three reported values for EBITDA were -$1.9 million (Q4 2025), -$1.5 million (Q3 2025), and -$686277.0 (Q2 2025) per Business Quant data.